^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    darleukin (L19IL2)

    i
    Other names: anti-EDB-IL2 antibody conjugate, L19IL2, L19-IL2 fusion protein, anti-EDB-interleukin-2 antibody conjugate, L19-IL-2, L19-IL2
    Associations

    News

    Trials
    Company:
    Philogen
    Drug class:
    IL-2 stimulant, Fibronectin 1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    21d
    L19IL2/L19TNF in Patients With Cutaneous Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=92, Not yet recruiting, Philogen S.p.A.
    New P2 trial
    |
    Nidlegy (darleukin/fibromun) • darleukin (L19IL2)
    22d
    L19IL2/TNF in Patients With Basal Cell Carcinoma (clinicaltrials.gov)
    P2, N=92, Not yet recruiting, Philogen S.p.A.
    New P2 trial
    |
    Nidlegy (darleukin/fibromun) • darleukin (L19IL2)
    23d
    L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC) (clinicaltrials.gov)
    P2, N=180, Not yet recruiting, Philogen S.p.A.
    New P2 trial
    |
    Nidlegy (darleukin/fibromun) • darleukin (L19IL2)
    10ms
    IMMUNOSABR2: IMMUNOtherapy and Stereotactic ABlative Radiotherapy (IMMUNOSABR) a Phase II Study (clinicaltrials.gov)
    P2, N=88, Terminated, Maastricht University Medical Center | Active, not recruiting --> Terminated; This trial is not transitioning to the Clinical Trial Regulation (CTR) EU No 536/2014.
    Trial termination
    |
    IL2 (Interleukin 2)
    |
    darleukin (L19IL2)
    11ms
    Theratri: A Study to Evaluate the Safety and Preliminary Signs of Efficacy of [177Lu]Lu-OncoFAP-23 Alone or in Combination with L19-IL2 As a Treatment of Metastatic FAP-positive Solid Tumors (clinicaltrials.gov)
    P1, N=56, Not yet recruiting, Philogen S.p.A. | Initiation date: Dec 2024 --> May 2025
    Trial initiation date
    |
    darleukin (L19IL2)
    1year
    Theratri: A Study to Evaluate the Safety and Preliminary Signs of Efficacy of [177Lu]Lu-OncoFAP-23 Alone or in Combination with L19-IL2 As a Treatment of Metastatic FAP-positive Solid Tumors (clinicaltrials.gov)
    P1, N=56, Not yet recruiting, Philogen S.p.A.
    New P1 trial • Combination therapy • Metastases
    |
    darleukin (L19IL2)
    over1year
    IMMUNOSABR2: IMMUNOtherapy and Stereotactic ABlative Radiotherapy (IMMUNOSABR) a Phase II Study (clinicaltrials.gov)
    P2, N=88, Active, not recruiting, Maastricht University Medical Center | Recruiting --> Active, not recruiting | N=126 --> 88
    Enrollment closed • Enrollment change • Metastases
    |
    IL2 (Interleukin 2)
    |
    darleukin (L19IL2)
    over1year
    IMMUNOSABR2: IMMUNOtherapy and Stereotactic ABlative Radiotherapy (IMMUNOSABR) a Phase II Study (clinicaltrials.gov)
    P2, N=126, Recruiting, Maastricht University Medical Center | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2022 --> Dec 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    IL2 (Interleukin 2)
    |
    darleukin (L19IL2)
    over1year
    Neoadjuvant L19IL2/L19TNF- Pivotal Study (clinicaltrials.gov)
    P3, N=214, Recruiting, Philogen S.p.A. | Trial primary completion date: Dec 2023 --> Oct 2024
    Trial primary completion date • Surgery
    |
    BRAF (B-raf proto-oncogene)
    |
    Nidlegy (darleukin/fibromun) • darleukin (L19IL2)
    2years
    A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) (clinicaltrials.gov)
    P1/2, N=6, Terminated, Philogen S.p.A. | Trial completion date: Dec 2022 --> Sep 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2022 --> Sep 2023; Slow progression due to difficulties in finding eligible patients. Competitive clinical trials with innovative agents and new approved products leaddefinitive stop.
    Trial completion date • Trial termination • Trial primary completion date • Combination therapy
    |
    CD20 (Membrane Spanning 4-Domains A1) • IL2 (Interleukin 2)
    |
    CD20 positive
    |
    Rituxan (rituximab) • darleukin (L19IL2)
    over3years
    A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) (clinicaltrials.gov)
    P1/2, N=6, Active, not recruiting, Philogen S.p.A. | Recruiting --> Active, not recruiting | N=38 --> 6 | Trial completion date: Dec 2019 --> Dec 2022 | Trial primary completion date: Dec 2019 --> Dec 2022
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy
    |
    CD20 (Membrane Spanning 4-Domains A1) • IL2 (Interleukin 2)
    |
    CD20 positive
    |
    Rituxan (rituximab) • darleukin (L19IL2)
    over3years
    A Phase I/II Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma (clinicaltrials.gov)
    P1/2, N=96, Active, not recruiting, Philogen S.p.A. | Trial completion date: Jun 2017 --> Jun 2022
    Trial completion date • Combination therapy
    |
    IL2 (Interleukin 2)
    |
    dacarbazine • darleukin (L19IL2)